ALX4 antibody - N-terminal region (ARP32356_P050)
- Known as:
- ALX4 (anti-) - N-terminal region (ARP32356_P050)
- Catalog number:
- arp32356_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ALX4 antibody - N-terminal region (ARP32356_P050)
Related genes to: ALX4 antibody - N-terminal region (ARP32356_P050)
- Gene:
- ALX4 NIH gene
- Name:
- ALX homeobox 4
- Previous symbol:
- PFM2
- Synonyms:
- FPP, PFM, KIAA1788
- Chromosome:
- 11p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-06-15
- Date modifiied:
- 2019-04-23
Related products to: ALX4 antibody - N-terminal region (ARP32356_P050)
Related articles to: ALX4 antibody - N-terminal region (ARP32356_P050)
- To elucidate how ALX Homeobox 4 (ALX4) modulates cisplatin sensitivity via DNA damage regulation in breast cancer (BC), this study explored the established role of mRNA-mediated DNA repair in driving chemoresistance. - Source: PubMed
Yan YanXia JianhongMa TingtingZhou Liqing - Iris pigmentation is a heritable trait with a complex genetic architecture. While the genetic basis of iris pigmentation has been extensively studied in humans, little is known about iris pigmentation in pigs. Iris pigmentation in pigs varies from different shades of brown or pale irises to heterochromia manifesting either as different colors between both irises (heterochromia iridum) or multiple colors within a single iris (heterochromia iridis). This study investigates the genetics of iris pigmentation variability in the Swiss Landrace and Swiss Large White pig breeds. - Source: PubMed
Publication date: 2026/03/25
Gorssen WimKadri Naveen KumarKhayatzadeh NegarLeonard Alexander SHe QiongyuMehrotra ArnavNeuenschwander StefanPausch Hubert - Accumulating evidence has revealed that epithelial-mesenchymal transition (EMT) plays a crucial role in tumor progression and the immune microenvironment, which further results in a high rate of recurrence and metastasis. The EMT immune signaling pathway provides a great perspective for designing personalized therapies. - Source: PubMed
Publication date: 2026/01/19
Liang WeiWang Zi-YingShao Quan-FengLi Yuan-YuanZhu BeiQin Xi-HuChen Wei-Xian - : Colorectal cancer (CRC) is a major contributor to cancer-related deaths worldwide. While existing screening tools are effective, their high cost and limited availability restrict widespread adoption, particularly in low- and middle-income settings. The identification of affordable, non-invasive biomarkers is therefore critical to improve early CRC detection and survival outcomes. : A systematic literature search was performed through PubMed, ScienceDirect, Medline, ISI Web of Knowledge, and Google Scholar to identify studies reporting stool- and blood-based biomarkers for CRC detection. Data were extracted using a standardized template, including study details, specimen type, detection method, and diagnostic performance parameters such as sensitivity and specificity. : DNA methylation biomarkers demonstrated high diagnostic potential. and achieved a combined stool sensitivity of 91.35%. Other methylation markers, including , , and , showed a composite sensitivity of 82.7%. Plasma-based methylation markers such as , , and reported sensitivities ranging from 18-47% and specificities of 93-99%. Hypermethylation of and achieved 81.3% sensitivity in CRC and precursor lesions. ( and ) were elevated in CRC patients, with stool yielding 72.2% sensitivity and 95% specificity. A stool gene panel (, , , ) reached 96.6% sensitivity and 89.7% specificity, while a methylation-based panel (, , , , , , ) achieved 90.7% sensitivity. MicroRNAs (, , , ) showed excellent diagnostic performance, with sensitivities exceeding 96% and specificities above 75%. : DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings. - Source: PubMed
Publication date: 2025/12/27
Hallom PumelelaNaidoo PragalathanSenzani SibusisoKader Sayed SMkhize-Kwitshana Zilungile L - Aberrant DNA methylation drives cancer development, yet current screening methods require substantial resources for targeted enrichment across multiple CpG-rich regions. Early cancer detection in cell-free DNA (cfDNA) presents additional challenges due to low circulating tumor DNA fractions (0.01-10%) that dilute cancer-specific signals. To address these limitations, we developed Restriction Enzyme-based CpG-methylated fragment AmPlification sequencing (RECAP-seq) to selectively enrich hypermethylated fragments from existing Enzymatic Methyl-seq (EM-seq) libraries. RECAP-seq combines EM-seq library preparation with BstUI restriction enzyme digestion to target CGCG motifs, achieving preferential enrichment of CpG islands. With spike-in experiments using cell line mixtures, RECAP-seq successfully distinguished samples as low as 0.001%. The method identified 7,091 hypermethylated markers, including ALX4 which showed progressive increases with colorectal cancer stage. Clinical validation using cfDNA from 35 healthy donors and 47 colorectal cancer patients demonstrated robust detection with an area under the curve (AUC) of 0.932, achieving 78.7% sensitivity at 95% specificity. - Source: PubMed
Publication date: 2025/11/19
Shin DongjuKim TaehoonLee JaywonKim Hwang-PhillKim Tae-YouBang Duhee